Maria Lia Palomba
Overview
Explore the profile of Maria Lia Palomba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benjamini O, Fried S, Shouval R, Flynn J, Beyar-Katz O, Leslie L, et al.
Haematologica
. 2024 Jun;
109(11):3566-3577.
PMID: 38899351
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a...
2.
Zhu M, Drill E, Joffe E, Salles G, Delgado A, Zelenetz A, et al.
Haematologica
. 2024 Mar;
109(7):2326-2330.
PMID: 38497151
No abstract available.
3.
Buske C, Palomba M
Hematol Oncol Clin North Am
. 2023 Jun;
37(4):719-725.
PMID: 37270384
Despite substantial progress in the clinical management of Waldenström's Macroglobulinemia (WM) and the emergence of chemotherapy-free approaches such as BTK inhibitors, WM is still a disease in which current treatments...
4.
Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S, Pajarillo R, et al.
Nat Med
. 2022 Oct;
29(11):2954.
PMID: 36253610
No abstract available.
5.
Corona M, Shouval R, Alarcon A, Flynn J, Devlin S, Batlevi C, et al.
Bone Marrow Transplant
. 2022 Sep;
57(12):1839-1841.
PMID: 36131002
No abstract available.
6.
Morschhauser F, Nastoupil L, Feugier P, Schiano De Colella J, Tilly H, Palomba M, et al.
J Clin Oncol
. 2022 Aug;
40(28):3239-3245.
PMID: 35947804
JCO The RELEVANCE trial (ClinicalTrials.gov identifier: NCT01650701) showed that lenalidomide plus rituximab (R) provided similar efficacy to rituximab plus chemotherapy (R-chemo) in patients with advanced-stage, previously untreated follicular lymphoma (FL)....
7.
Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S, Pajarillo R, et al.
Nat Med
. 2022 Mar;
28(4):713-723.
PMID: 35288695
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and...
8.
Palomba M, Cartron G, Popplewell L, Ribrag V, Westin J, Huw L, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Feb;
22(7):504-512.
PMID: 35151584
Background: The combination of atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) and inhibits the interaction between PD-L1 and its receptors, and tazemetostat, an EZH2 inhibitor, may lead...
9.
Shouval R, Tomas A, Fein J, Flynn J, Markovits E, Mayer S, et al.
J Clin Oncol
. 2021 Dec;
40(4):369-381.
PMID: 34860572
Purpose: Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental to response outcomes in...
10.
Pennisi M, Sanchez-Escamilla M, Flynn J, Shouval R, Tomas A, Silverberg M, et al.
Blood Adv
. 2021 Aug;
5(17):3397-3406.
PMID: 34432870
Patients who develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability and endothelial activation. The EASIX (Endothelial Activation...